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Introduction
Detection of circulating tumor cells (CTCs) in peripheral 
blood and disseminated tumor cells (DTCs) in bone 
marrow of tumor patients has become an active area of 
translational cancer research, with numerous groups 
develop  ing new diagnostic assays and more than 200 
clinical trials incorporating CTC counts as a biomarker 
in patients with various types of solid tumors. Among 
these activities, breast cancer has played the most 
prominent role as a ‘driver’ of research on CTCs/DTCs. 
Th   e clinical relevance of DTCs is already well-established 
[1,2] and has been conﬁ   rmed by diﬀ  erent  large-scale 
studies, including a pooled analysis on almost 5,000 
patients [3]. Aspirations of bone marrow, a common 
homing organ for many types of solid tumors [1,4], are 
part of the routine screening of leukemia patients and are 
much less diﬃ     cult to perform than biopsies of other 
organs (for example, lungs or liver). Nevertheless, it is 
still a painful and invasive procedure that is not com-
fortable for patients and, due to this fact, has not yet been 
accepted for routine diagnosis of solid tumors. In 
contrast, CTCs are easier to obtain by peripheral blood 
sampling, which can be repeated frequently, allowing 
real-time monitoring of metastatic progression. Th  us,  it 
seems that peripheral blood might serve as a perfect 
alternative source of material to diagnose cancer patients, 
and CTC analysis in cancer patients has thus been 
termed a ‘liquid biopsy’ [5].
On the other hand, detection of CTCs is hampered by 
the still uncertain biology of these cells, which most likely 
inherit a heterogeneous malignant potential to home and 
give rise to overt metastasis in secondary organs. Even 
modern technologies that have been applied to isolate 
and characterize CTCs still need to be improved [6]. 
Although recent results on signiﬁ  cant associations between 
the presence of CTCs and subsequent occurrence or 
progression of metastases are encouraging, the clinical 
relevance and utility of CTCs merit further investigation 
and conﬁ  rmation by multicenter trials.
Developments in CTC/DTC technologies over the past 
few years have been impressive. Th   is review will 
recapitulate the current knowledge on CTCs in breast 
cancer patients with a focus on the biology and clinical 
relevance of these cells.
Tumor cell dissemination: a complex process
During tumorigenesis subsets of tumor cells localized 
within the primary tumor might acquire features of 
invasiveness and motility and enter blood or lymph 
vessels (Figure 1). Mechanisms involved in this process 
are still under investigation; however, they are already 
reported to be linked to variable interactions between 
tumor cells and the surrounding stroma, including, for 
example, response to hypoxia and metalloproteinase-
dependent invasion into surrounding tissue, (neo-)vas-
culari  zation of a tumor [7], as well as gain of a phenotype 
revealing signatures of epithelial-mesen  chymal transition 
(EMT) observed in at least a subpopulation of tumor 
cells with certain ‘stemness’ properties [8-10].
Once cells spread and survive, they might establish a 
separate secondary tumor site in a new environment of a 
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brain). CTCs/DTCs, however, can also undergo apoptosis 
or persist in an inactive, so-called dormant state for years 
[11]. CTCs that extravasate need to survive as DTCs in 
their new microenvironment, which might be supported 
by ﬁ   nding and/or establishing a proper niche. Th  ese 
DTCs might transform into more aggressive variants and 
grow out to overt metastasis [7] and/or they may re-
circulate to other secondary organs or even back to their 
primary tumor site [12,13].
Dissemination might appear in a late phase of 
tumorigenesis when a primary tumor achieves a critical 
mass of cells and gains a highly aggressive phenotype 
(linear model) or it might be initiated much earlier, even 
when a malignant tumor is still of small size (parallel 
model) [14]. In the linear model subsequent events 
gradually lead to tumor progression, whereas in the 
concurrent parallel model CTCs/DTCs settle down in 
distant organs, creat  ing a clone that evolves in parallel to 
a primary site. In both models occurrence of metastasis is 
usually fatal for a patient.
Circulating tumor cell detection
CTC detection remains a big technical challenge despite 
the continued development of many new exciting tech-
nologies [1]. Th  e key problem is to deﬁ  ne a technology 
that will detect the real metastasis-initiating CTC that 
will give rise to distant metastases. It is conceivable that 
this will be a combination of complementary technologies 
or even several technologies optimized for speciﬁ  c tumor 
types, including breast cancer. Some of the current key 
technologies for the enrichment and detection of CTCs 
are listed in Table 1. As CTCs occur at very low concen-
trations of one tumor cell in a background of millions of 
blood cells, enrichment is usually required prior to CTC 
detection. CTC enrichment involves a large panel of 
tech  nologies based on the diﬀ  erent properties of CTCs 
that distinguish them from the surrounding normal 
hematopoietic cells: physical properties (size, density, 
electric charges, deformability) and/or biological proper-
ties (surface protein expression, viability and invasion 
capacity). It is important to note that most of the current 
technologies are still based on epithelial cell adhesion 
Figure 1. Phenotypic changes of breast cancer cells during dissemination and metastasis. Epithelial tumor cells that originated from 
a primary tumor might transform into more aggressive phenotypes and disseminate into the blood or lymph circulation. Due to this altered 
phenotype, which is frequently associated with epithelial-mesenchymal transition (EMT), their detection and identifi  cation in blood of cancer 
patients is signifi  cantly hampered. After surviving in the blood stream and homing to a secondary organ, tumor cells may undergo mesenchymal-
epithelial transition (MET) and assimilate into the new environment of their secondary site (for example, bone marrow). This process will lead to the 
establishment of occult micrometastases that may eventually grow out to overt metastases detectable with current imaging methods.
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Page 2 of 11Table 1. Current technologies for CTC detection
Assay system  Enrichment  Detection  Comments
EPCAM-based assays
CellSearch® system Immunomagnetic beads: 
EpCAM-Ab-coupled 
ferrofl  uid
Immunocytochemistry:
Positive for CK8, 18, 19
Negative for CD45
Nucleus positive for DAPI
Semi-automated system with FDA approval for metastatic 
breast, colon and prostate cancer. CTC can be enumerated and 
visualized [2]
CTC-chip Microposts: EpCAM-Ab-
coupled microposts
Immunocytochemistry:
Positive for CK8, 18, 19
Negative for CD45
Nucleus positive for DAPI
High detection rate (approximately 100%) even in M0-patients 
warrants further investigations on assay specifi  city; the 
Herringbone second generation of this microchip is more 
specifi  c. Needs to be validated in clinical trials [67-70]
CTC-chip Ephesia Column of nanobeads: 
EpCAM-Ab-coupled 
ferrofl  uids
Immunocytochemistry:
Positive for CKs
Negative for CD45
Nucleus positive for DAPI
Lack of validation studies in clinical settings [71]
MagSweeper Immunomagnetic beads: 
EpCAM-Ab-coupled 
ferrofl  uids
Microscope visualisation:
Morphology
Isolation of CepC with a high degree of purity. Analysis of large 
blood volume [72]
Laser scanning 
cytometry Maintrac®
RBC lysis Immunocytochemistry:
Positive for EpCAM
Negative for CD45
High incidence of positive events up to 3 logs higher CTC 
counts than those obtained with other techniques warrants 
further investigations of assay specifi  city [73]
Ikoniscope® imaging 
system
Ficoll-Isopaque or 
fi  ltration with track-etched 
membranes
Immunocytochemistry:
Positive for EpCAM, CK7/8
PSA (prostate only)
FISH: chromosomes 7 and 8 
Nucleus positive for DAPI
Two epithelial specifi  c Abs and FISH to detect chromosomal 
abnormalities in CTCs [74]
Ariol® system RBC lysis, then 
immunomagnetic beads: 
CK-Ab- + EpCAM-Ab-
coupled ferrofl  uids
Immunocytochemistry:
Positive for CK8, 18, 19
Negative for CD45
Nucleus positive for DAPI
Detection of EpCAM+ and EpCAM- CTCs [75]
AdnaTest Immunomagnetic beads: 
MUC1-, EpCAM-Ab-coupled 
microbeads
Molecular biology: RT-PCR
Positive for at least one of the following 
markers: MUC1, HER2, EpCAM
AdnaTest also does not quantify the tumour cell load, false 
positive results due to unspecifi  c amplifi  cation, no further 
analysis possible [76]
Functional assays
EPISPOT assay Rosette plus Ficoll:
Depletion of CD45+ cells
Secretion of proteins:
CK19, MUC1, Cath-D (breast); CK19 
(colon); PSA (prostate); TG (thyroid)
Detection of viable epithelial secreting-cells; unbiased 
enrichment independent of CTC/DTC phenotype [41,77]
Vita-AssayTM or 
Collagen Adhesion 
Matrix (CAM) 
technology
Invasion capacity:
Ingestion of fl  uorescent 
CAM fragments (CAM+)
Immunocytochemistry:
Positive for EpCAM, ESA, pan-CK 4, 5, 6, 
8, 10, 13 and 18
Negative for CD45
Detection of CTCs with the invasive phenotype in blood [78]
Others
ISET Cell size Immunocytochemistry:
Positive for CK
Nucleus: Mayer’s hematoxylin
Sensitivity threshold of one carcinoma cell per milliliter of 
blood; HER2 amplifi  cation determined by real-time PCR on DNA 
extracted from CK immunostained cells (CTCs) collected by laser 
microdissection from selected ISET-positive fi  lters; the possibility 
of false-positive diagnosis stresses the need for using ancillary 
methods to improve this approach [79-81]
FAST (fi  ber-optic 
array scanning 
technology)
No pre-enrichment Immunofl  uorescence:
Positive for CK
Nucleus positive for DAPI
Morphology
Rare cells detected by laser scanning to almost 1,000 times faster 
than digital microscopy [82,83]
DEP-FFF 
(dielectrophoretic 
fi  eld-fl  ow 
fractionation)
Phenotype - membrane 
capacitance
Immunocytochemistry:
Wright stain
No need for labeling or modifi  cation of CTCs; PBMC/CTC ratio is 
enriched more than 2000-fold; CTCs isolated by DEP are viable 
and suitable for a wide spectrum of analyses [84]
Versatile label free 
biochip
Cell size deformability Immunofl  uorescence:
Positive for CK
Negative for CD45
Nucleus positive for DAPI
Morphology
Label free selection and CTCs are viable after blood processing 
[85]
Abbreviations: Ab, antibody; BM, bone marrow; Cath-D, cathepsin D; CepC, circulating epithelial cell; CK, cytokeratin; CTC, circulating tumor cell; DAPI, 4’,6-diamidino-
2-phenylindole; DEP, dielectrophoresis; DTC, disseminated tumor cell; EpCAM, epithelial cell adhesion molecule; EPISPOT, EPIthelial immunoSPOT; ESA, epithelial 
specifi  c antigen; FDA, Food and Drug Administration; FISH, fl  uorescent in situ hybridization; ISET, isolation by size of epithelial tumor cells; MUC1, mucine 1; NSCLC, 
non-small-cell lung cancer; PBMC, peripheral blood mononuclear cells; PSA, prostate specifi  c antigen; RBC, red blood cell; RT-PCR, reverse transcription polymerase 
chain reaction; TG, thyroglobulin.  
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to the assumption that EMT may occur particularly dur-
ing tumor cell dissemination and this might be accom-
panied by EpCAM downregulation, new emerging tech-
nologies also try to capture EpCAM-negative CTCs 
(Table 1).
As outlined in more detail below, an ideal CTC detec-
tion method might include epithelial markers not 
repressed during EMT and/or mesenchymal markers 
induced during EMT. Moreover, it is important to distin-
guish viable from apoptotic CTCs to detect and proﬁ  le 
the most relevant metastasis-initiating CTCs. Finally, it is 
crucial to be able to analyze the captured CTCs at the 
molecular level and to compare their characteristics to 
those of the primary tumor and overt metastases.
Th   ere is now strong interest in developing microdevices 
that can handle sample volumes at least ten times smaller 
than those required for current tests (<1  ml of blood 
versus 5 to 20 ml), thereby minimizing assay time and the 
use of expensive staining reagents. However, CTCs are 
very rare and the analysis of larger blood volumes 
(≥20 ml) might be preferable, particularly in early-stage 
cancer patients with a small burden of CTCs. Th  us, 
technologies that can handle larger blood volumes still 
deserve special attention.
Th   e current CTC devices need to implement physical 
know-how and information on the biology of tumor cell 
dissemination, and intense clinical validation of these 
devices is required before their introduction into the 
management of cancer patients.
Clinical relevance of circulating tumor cells
Clinical utility of circulating tumor cells as a prognostic 
marker
CTC detection is possible at both early and late stages of 
cancer development and might allow estimation of the 
risk of relapse and survival. Yields of these rare cells range 
from one identiﬁ  ed cell up to several hundreds of cells 
per blood sample. It is still under debate whether the 
presence of one cell might be clinically relevant and what 
CTC count thresholds should be used in order to 
establish disease-free or overall survival. Most research 
groups apply a prognostic cut-oﬀ   of ﬁ  ve CTCs as estab-
lished by Cristofanilli and colleagues in metastatic breast 
cancer patients [15,16].
Yields of tumor cells separated from peripheral blood 
are low in metastatic breast cancer but are still suﬃ   cient 
for further analysis; in early stages of breast cancer, 
however, these counts are even lower and frequently do 
not exceed ﬁ  ve CTCs per 7.5 to 10 ml of blood [2]. Identi-
ﬁ  cation of CTCs at this stage of disease is still a challenge. 
Nevertheless, the ﬁ  nding of even a single CTC in a blood 
volume as small as 7.5 ml was shown to associate with an 
increased risk for subsequent metastases [17,18], which 
suggests that CTCs might metastasize more eﬃ   ciently 
than deduced from animal experiments [7].
Although most CTC studies are performed on subjects 
with metastatic breast cancer, CTC technologies might 
have the greatest impact on the treatment of patients 
without overt metastasis. CTC detection was proven to 
predict prognosis in clinically relevant subgroups of 
early-stage breast cancer patients [4,19]. Th   e still ongoing 
German ‘SUCCESS’ trial, which has enrolled almost 
1,500 lymph node-positive and high-risk lymph node-
negative but metastasis-free breast cancer patients before 
and after taxane-based adjuvant therapy, deﬁ  ned that at 
least one CTC was evident in 10% of the patients at the 
time of primary diagnosis before adjuvant therapy, and a 
signiﬁ  cantly better prognosis was detected in the groups 
with persistently negative CTC status [20].
Circulating tumor cells as predictor of response to therapy
Predicting patients’ responses to therapeutic regimens is 
probably one of the most exciting applications of CTC 
technology. Consequently, several studies have suggested 
that the presence of CTCs that have survived therapy 
might reﬂ  ect a failure of systemic therapy [21,22]. Estab-
lishing that CTCs indicate progression during chemo-
therapy even 7 to 9 weeks before radiological imaging 
does so, Liu and colleagues [23] provided the ﬁ  rst strong 
evidence that CTC tests might replace imperfect 
standard imaging procedures in the future.
Maintaining less than ﬁ  ve CTCs or decreasing CTC 
counts during therapy is considered to be an indicator of 
good response to treatment. RT-PCR-based detection of 
cytokeratin (CK)19 mRNA-positive CTCs after adjuvant 
therapy in early breast cancer patients was reported to be 
an independent risk factor for resistant residual disease 
[24]. CTC counts in 115 non-metastatic breast cancer 
patients before and after primary systemic chemotherapy 
in a phase II trial (REMAGUS02) was an independent 
prognostic factor for shorter metastasis-free survival but 
did not correlate with pathologic complete response of the 
primary tumor to therapy [17,25]. In the ‘GEPARQuattro’ 
trial,  which included 213 non-metastatic  breast cancer 
patients, the prevalence of CTC-positive patients dropped 
from 22% before to 11% after neo-adjuvant therapy and 
again no associations were found with primary tumor 
response [26].
It has been suggested that CTC counts might depend 
on the form of treatment. For example, the humanized 
monoclonal antibody bevacizumab, which recognizes 
vascular endothelial growth factor A, combined with 
ﬁ  rst-line chemotherapy modiﬁ  ed the predictive value of 
CTCs during treatment of metastatic breast cancer 
patients, possibly due to impaired tumor-cell intra-
vasation through blood vessel endothelium [27].
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oﬀ  er the possibility of an immediate change of therapy 
instead of waiting for classic clinical-radiological evidence 
of progressive disease. Ongoing studies aim to answer the 
question of whether individualization of treatment deci-
sions can indeed be based on CTC levels (for example, 
Southwest Oncology Group randomized trial SWOG 
S0500 on metastatic breast cancer patients [28], German 
Breast Group GEPARQuattro trial on  non-metastatic 
breast cancer patients [29], and SUCCESS trial on non-
metastatic breast cancer patients [30]). Th  e  ﬁ  rst example 
of potential clinical beneﬁ   t arising from a change in 
therapeutic regimen on the basis of CTC count is the 
case report on a metastatic breast cancer patient ﬁ  rst 
treated with HER-2-targeting trastuzumab and subse-
quently with the dual epithelial growth factor receptor 
(EGFR) and HER-2 inhibitor lapatinib [31]. Indeed, the 
change in therapy resulted in the depletion of EGFR-
positive CTCs and response of the primary tumor. Tumor 
progression was related to recurrence of CTCs that were 
both HER-2 and EGFR negative, suggesting therapy-
induced selection of target-negative metastatic cells.
Relation between CTCs in blood and DTCs in bone marrow
Th   ough initial investigations have provided evidence that 
CTCs might be a promising prognostic marker, it is still 
unclear whether they provide the same clinical infor  ma-
tion as DTCs. To the best of our knowledge, comparative 
analyses of CTCs and DTCs have been performed in only 
a few studies.
Th   e yield of CTCs was estimated to be lower than that 
of DTCs [32] but this depends on the techniques used for 
CTC/DTC detection. Some authors reported that it 
reached greater levels only in bone marrow-positive 
cases [21,33] and in high-risk patients [22]. CTCs and 
DTCs are detected in individual patients at the same time 
with variable con  cordance rates (Table  2). Diﬀ  erences 
observed in some studies might be explained to some 
extent by the diﬀ  erent technologies used to detect CTCs 
and DTCs. Interest  ingly, higher overall discordance of 
CTC and DTC counts was found in patients after rather 
than before adjuvant therapy [34], which suggests 
diﬀ   erential sensi  tivity of DTCs and CTCs to chemo-
therapy. In this context, it might be noteworthy that 
DTCs may express a set of stress response proteins that 
may help them to survive chemotherapy [35].
Controversy also remains regarding the clinical rele-
vance of CTCs versus DTCs. Some authors showed 
superior performance of DTCs in predicting overall 
survival in both non-metastatic and metastatic breast 
cancer patients [32,36]. In contrast, others reported that 
CTCs predict overall survival in metastatic patients, 
whereas DTCs do not [37]. Pierga and colleagues [38] 
reported that CTCs and DTCs have identical impact on 
overall survival of non-metastatic and metastatic patients 
but disease-free survival is predicted only by DTCs. 
Table 2. Comparison of CTC and DTC detection in breast cancer
                               n (%)
      Total       
 Patient   number  CTC+,  CTC+,  CTC-,  CTC-,  Concordance 
Detection  method  status  Remarks  of  patients  DTC+ DTC- DTC+ DTC-  (%)  Reference
Pan-CK staining  M0 and M1  -  114  26 (22.8)  2 (1.7)  41 (35.9)  45 (39.4)  62.3  [35]
Pan-CK staining  M0 and M1  -  53  3 (5.6)  2 (3.7)  6 (11.3)  42 (79.2)  84.9  [21]
RT-PCR  M0 and M1  Detection of CK19  148  8 (5.4)  14 (9.5)  34 (22.9)  92 (62.2)  67.5  [33]
CK19 or mammaglobin  M0 and M1  Detection of mammaglobin  148  11 (7.4)  18 (12.2)  19 (12.8)  100 (67.6)  75.0  [33]
CK-staining  M0  -  341  8 (2.3)  26 (7.6)  40 (11.7)  267 (78.3)  80.6  [29]
Pan-CK staining  M0 and M1  -  39  12 (30.8)  3 (7.6)  12 (30.8)  12 (30.8)  61.5  [34]
RT-PCR, CK19  M0  Patients before   165  88 (53.3)  3 (1.8)  7 (4.2)  67 (40.6)  93.9  [31]
   neo-adjuvant  therapy
    Patients after   84  32 (38.1)  12 (14.2)  11 (13.1)  29 (34.5)  72.6  [31]
   neo-adjuvant  therapy
CellSearch®, RT-PCR  M0  High-risk patients  27  16 (59.2)  4 (14.8)  3 (11.2)  4 (14.8)  74.1  [22]
Pan-CK staining, CellSearch®  M0  -  63  5 (7.9)  13 (20.6)  15 (23.8)  30 (47.6)  55.5  [18]
            
Avarage            72.8 
Minimum            55.5  [18]
Maximum            93.9  [31]
Abbreviations: M0, no detected metastasis; M1, metastasis; n, number of patients; RT-PCR, reverse transcription polymerase chain reaction.
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be associated with an especially poor prognosis and 
increased incidence of disease-related deaths in non-
metastatic breast cancer patients [32,34].
Of note, it has recently been reported that counts of 
disseminating tumor cells vary not only between bone 
marrow and peripheral blood but probably depend also 
on the vascular compartment from which blood is being 
collected [39]. Substantially higher numbers of CTCs 
were counted in central veins than in peripheral veins. It 
might be speculated that the numbers of DTCs/CTCs 
might be site-speciﬁ  c because the microvascular system 
of diﬀ   erent organs might have a variable potency for 
ﬁ  ltering CTCs/DTCs.
Biology of circulating tumor cells
Viability and proliferative activity of circulating tumor cells
CTCs separated from peripheral blood of cancer patients 
seem to represent a heterogonous pool of tumor cells 
(Figure 2) with an average half-life of 1 to 2.4 hours [40]. 
CTCs found in peripheral blood might be apoptotic or 
viable but most currently applied assays do not discri  mi-
nate this status. Th   ey also do not distinguish cycling and 
non-cycling CTCs. Both features, however, might signiﬁ  -
cantly inﬂ  uence overall response to therapies.
To the best of our knowledge, the ﬁ  rst test for detecting 
viable disseminating breast tumor cells was the EpiSpot, 
which detects them according to their secretion of CK19 
and MUC-1 (Figure 2) [41]. More recently, the addition 
of the early apoptosis marker M30 to classic cytokeratin 
staining has enabled assessment of the ratio of viable to 
dead CTCs [42] (Figure 2).
Expression of the nuclear protein Ki-67, which is 
associated with cell proliferation, was reported to be 
absent or rare in CTCs of breast cancer patients [21,43] 
(Figure 1), which implies that these cells might display 
the phenotype of non-cycling, so-called dormant cancer 
cells. Th   ese non-dividing cells might also not respond to 
some of the currently used chemotherapeutics, as 
indicated by the fact that a fraction of CTCs survives 
these therapies (see above).
Expression of epithelial marker genes on circulating tumor 
cells
Classic epithelial markers such as EpCAM or certain CKs 
are frequently not suﬃ     cient to detect the entire CTC 
population in blood [44]. It was reported that the 
CellSearch® method, based on the detection of EpCam 
antigen, does not recognize normal-like breast cancer 
cells, which in general demonstrate aggressive features 
[45]. Only a method using another marker, CD146 (also 
called MCAM or MUC18), enabled assessment of 
reliable numbers of CTCs in advanced normal-like breast 
cancer patients [46]. One explanation for why CTC 
isolation based on classic epithelial markers does not 
detect all tumor cells in peripheral blood is that single 
antibodies, sold as ‘broad spectrum’ or ‘pan’ CK anti-
bodies, do not detect all CK proteins expressed in breast 
cancer cells [47]; thus, only appropriate cocktails of CK 
antibodies increase overall detection rates and reduce the 
risk of false-negative ﬁ  ndings.
Recent work on EpCAM signaling [48] sheds new light 
on a probable altered phenotype of CTCs. Commercially 
available antibodies against this glycoprotein recognize 
only its extracellular domain, whereas EpCAM might be 
cleaved by proteases, which in turn leads to relocation of 
its intracellular domain into the cell nucleus. Interest-
ingly, cells with EpCAM in their nuclei but not on the 
cellular membrane might be oncogenic in vivo [48]. It 
seems that expression and cleavage of EpCAM is asso-
ciated with a temporary need for proliferation of tumor 
cells [48], which might be essentially reduced when 
tumor cells enter the bloodstream. Th  us, it might be 
specu  lated that EpCAM-positive tumors also release cells 
that lose this molecule from the cellular membrane 
during extravasation and re-express it only in metastatic 
sites.
Partial mesenchymal transition of circulating tumor cells
Another reason that certain pools of CTCs might be 
missed during standard epithelial marker-based screen-
ing might be their altered phenotype resulting from EMT, 
currently dynamically investigated in terms of tumor 
aggressiveness. Epithelial tumor cells under speciﬁ  c 
external stimuli or with internal aberrations might trans-
form into cells with a mesenchymal or semi-mesen  chy-
mal phenotype [9,49]. Expression of epithelial markers in 
such cells might be limited or weak, which might lead to 
false-negative results in CTC tests.
Cell lines derived from DTCs isolated from bone 
marrow of cancer patients indeed demonstrate signatures 
of EMT, such as low relative levels of epithelial CKs (CK7, 
CK8, CK17, CK18 and CK19) and increased expression 
of the mesenchymal intermediate ﬁ  lament vimentin [35]. 
Several groups investigated this phenomenon in peri-
pheral blood of breast cancer patients using variable 
EMT-associated markers. Aktas and colleagues [50] 
observed at least one of the selected EMT markers (Twist 
1, Akt2 or PI3Kalpha) in 62% of CTC-positive and 7% of 
CTC-negative cancer patients (Figure  2). In contrast, 
another research group using a set of EMT-initiating 
transcription factors (Twist, Snail1, Slug, Zeb1 and 
FoxC2; Figure 2) showed that overexpression of at least 
one of these factors was detected in only 15.4% of 
patients [51]. Raimondi and colleagues [52] reported the 
presence of two EMT markers, vimentin and ﬁ  bronectin, 
in both CK-positive and -negative cells in the blood of 
28% and 38% of patients, respectively. Similarly, 
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and/or vimentin were expressed more frequently in CK-
negative than in CK-positive blood samples (EMT 
marker posi  tivity in 55% versus 43% of samples, 
respectively; Figure 2). Both groups noted no expression 
of these proteins in blood of healthy donors. Th  ese 
published studies suggest that a pool of CTCs might have 
a semi-mesenchymal phenotype.
It is important to mention that patients receiving neo-
adjuvant therapy were more likely to exhibit over-
expression of EMT markers than those who did not [51]. 
It was also demonstrated that EMT markers predicted 
worse prognosis more accurately than epithelial markers 
and even predicted it with statistical signiﬁ  cance  in 
patients with CK-negative blood samples [53]. Th  ese 
results imply that CTCs undergoing EMT might be a 
population of invasive cells resistant to neo-adjuvant 
therapy. Th   ey also demonstrate that EMT markers such 
as vimentin might complement epithelial markers for 
CTC detection, as indicated in prostate cancer [54]. 
However, vimentin is also expressed in a subpopulation 
of diﬀ  erentiated and/or activated monocytes [55], which 
can signiﬁ   cantly hinder identiﬁ   cation of CTCs in 
monocyte-rich fractions. Th   us, it is apparent that EMT-
related markers that are speciﬁ  c for CTC detection are 
urgently needed.
Putative stem cell-like phenotype of circulating tumor cells
EMT and stemness of tumor cells seem to be linked 
mechanistically [10,56,57]. Consequently, subpopulations 
Figure 2. Frequency of molecular markers expressed in circulating tumor cells of breast cancer patients. The shown frequencies are based 
on data from the literature [21,26,33,42-53,58,59,61-65,75,86-91] and they refer to the reported frequency (percentage of total number of circulating 
tumor cells (CTCs) detected in the particular report) of CTCs positive for the described marker. Markers for which there is more than one report 
are presented as the mean value and standard deviation of the available data in the literature. Abbreviations: ALDH1, aldehyde dehydrogenase 
1; CK19, cytokeratin 19; EC, epithelial cell; EGFR, epithelial growth factor receptor; EMT, epithelial-mesenchymal transition; EpCAM, epithelial cell 
adhesion molecule; ERalpha, estrogen receptor alpha; Her-2, epithelial growth factor receptor type 2; HIF-1, hypoxia-inducible factor 1; MAGEA3, 
melanoma-associated antigen 3; MRP, multidrug resistant protein; Muc-1, mucin 1; p-EGFR, phosphorylated epithelial growth factor receptor; pFAK, 
phosphorylated focal adhesion kinase; PgR, progesterone receptor; PI3K, phosphatidylinositol 3-kinase; SC, stem cell; VEGF, vascular endothelial 
growth factor; ZEB1, zinc fi  nger E-box-binding homeobox 1.
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Page 7 of 11of CTCs/DTCs may demonstrate a stem cell-like 
phenotype. Using diﬀ  erent experimental set-ups, (over)-
expression rates of the putative stem cell marker ALDH1 
in CTC-positive blood samples of breast cancer patients 
ranged from 46% [52] to approximately 70% [50] (Figure 2). 
As expected, ALDH1 was shown to be associated with 
EMT markers in these samples [50,52] and a higher stage 
of breast cancer [52]. Another group analyzed a total of 
1,439 CTCs and determined that 35.2% of CTCs had the 
stem cell-like phenotype CD44+/CD24-/low in 20 patients 
and 17.7% of CTCs with the stem cell-like phenotype 
ALDH1high/CD24-/low in 7 patients [58] (Figure 2).
Considering the cancer stem cell model, self-renewal 
potency and resistance to variable chemotherapeutics 
make putative cancer stem cells particularly diﬃ   cult to 
eradicate during medical intervention. In concordance, 
patients with ALDH1-positive CTCs more frequently did 
not respond to chemotherapy [50]. Recently, it was also 
demonstrated that CTCs in 86% of metastatic breast 
cancer patients expressed one or more diﬀ  erent multi-
drug resistance-related proteins (MRP1, MRP4, MRP5 
and MRP7), thought to be characteristic for putative 
cancer stem cells or at least tumor cells resistant to 
chemotherapy [59] (Figure 2). Th  e patients with MRP-
positive CTCs had signiﬁ  cantly shorter time to progres-
sion [59].
Altered geno-/phenotype of CTCs in comparison to the 
primary tumor
Currently, molecular diagnostics of cancer patients 
focuses on primary tumors. However, the tumor mass at 
the primary site contains both invasive and non-invasive 
tumor cells, whereas for the assessment of risk of relapse 
or progression only invasive cells seem to be clinically 
relevant. CTCs represent a pool of tumor cells that have 
already spread in the system and are ready to establish 
themselves in a host organ; they are thus potentially 
dangerous from a clinical point of view. Dissimilarities 
between CTCs and their respective primary tumor might 
inﬂ  uence a patient’s response to therapies selected only 
on the basis of the characteristics of the primary tumor 
[60,61]. Discrepancies in the phenotypes of CTCs and the 
primary tumor are indeed noted relatively frequently. 
HER-2-positive CTCs were demonstrated to occur in 
patients with HER-2-negative primary breast cancer and, 
conversely, HER-2-negative CTCs were observed in 
patients with HER-2-positive tumors [26,43,59,61-64]. 
Similar divergence was reported for EGFR [64], estrogen 
receptor alpha [59,65] and progesterone receptor [65]. 
Th  is phenomenon might be explained by limitations of 
the used experimental set-ups and methods - for 
example, omitting clinically relevant but small clones of 
tumor cells within the primary tumor site displaying 
aberrant HER-2 gene/protein dosages. However, CTCs 
might undergo a strong selection during dissemination or 
systemic treatment and their genomic instability may 
lead to the generation of new tumor cell clones with 
phenotypic/genotypic features diﬀ  erent to those of the 
primary tumor cells. In addition, CTCs might also be 
delivered to the blood circulation from secondary sites 
[11,13] and therefore their genotype/phenotype might 
resemble cells from occult metastatic sites instead of 
those from the primary site. Taken together, direct 
assess  ment of CTCs for therapeutic targets or intra-
cellular pathways interfering with the mode of action of 
the particular drug may provide valuable information in 
addition to current primary tumor analyses.
Conclusions
A ‘liquid biopsy’ that can determine CTC yields and 
characteristics in the blood of cancer patients has the 
potential to become one of the most promising tests in 
oncology, equivalent to the blood glucose measurement 
available for insulin treatment in diabetes patients [66]. 
Th   e reported data are very encouraging, but multicentre 
studies including larger cohorts of patients, longer 
observation periods, more detailed molecular characteri-
zation of CTCs and more standard  ized procedures are 
still needed in order to estimate the clinical utility of 
CTCs as an independent biomarker. Future analyses 
should focus on the nature of CTCs and show whether 
changes in their counts and properties can predict 
patient response to speciﬁ  c therapies and thereby com-
ple  ment current diagnostic tests.
Abbreviations
CK, cytokeratin; CTC, circulating tumor cell; DTC, disseminated tumor cell; 
EGFR, epithelial growth factor receptor; EMT, epithelial-mesenchymal 
transition; EpCAM, epithelial cell adhesion molecule; RT-PCR, reverse 
transcription polymerase chain reaction.
Competing interests
KP has received research grants and speaker’s honoria from Veridex. CAP has 
received honoraria from Veridex. NBK has no potential confl  ict of interest to 
declare.
Authors’ contributions
All authors contributed to the writing of the manuscript.
Acknowledgements
This work was supported by grants from the Bundesministerium für Bildung 
und Forschung, the European Commission (DISMAL-project, contract no. 
LSHC-CT-2005-018911). The authors apologize to all research groups whose 
excellent work was not acknowledged in the current review due to space 
limitations.
Author details
1Department of Tumour Biology, University Medical Centre Hamburg-
Eppendorf, Martinistr. 52, 20246 Hamburg, Germany. 2University Medical 
Centre, Saint-Eloi Hospital, Institute of Research in Biotherapy, Laboratory of 
Rare Human Circulating Cells, 80 avenue Augustin Fliche, 34295 Montpellier 
Cedex 5, France. 3University Medical Centre, Laboratory of Cell and Hormonal 
Biology, Arnaud de Villeneuve Hospital, 37, avenue du Doyen Gaston Giraud, 
34295 Montpellier Cedex 5, France. 4University Institute of Clinical Research 
UM1 - EA2415 - Epidemiology, Biostatistics and Public Health, 641 avenue du 
Doyen G. Giraud, 34093 Montpellier Cedex 5, France.
Bednarz-Knoll et al. Breast Cancer Research 2011, 13:228
http://breast-cancer-research.com/content/13/6/228
Page 8 of 11Published: 1 November 2011
References
1.  Pantel K, Brakenhoff   RH, Brandt B: Detection, clinical relevance and specifi  c 
biological properties of disseminating tumor cells. Nat Rev Cancer 2008, 
8:329-340.
2.  Pantel K, Alix-Panabières C, Riethdorf S: Cancer micrometastases. Nat Rev Clin 
Oncol 2009, 6:339-351.
3.  Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Jückstock J, Borgen 
E, Rack B, Braun S, Sommer H, Solomayer E, Pantel K, Nesland J, Friese K, 
Naume B: Persistence of disseminated tumor cells in the bone marrow of 
breast cancer patients predicts increased risk for relapse – a European 
pooled analysis. Clin Cancer Res 2011, 17:2967-2976.
4.  Pantel K, Brakenhoff   RH: Dissecting the metastatic cascade. Nat Rev Cancer 
2004, 4:448-456.
5.  Pantel K, Alix-Panabières C: Circulating tumour cells in cancer patients: 
challenges and perspectives. Trends Mol Med 2010, 16:398-406.
6.  Wicha MS, Hayes DF: Circulating tumor cells: not all detected cells are bad 
and not all bad cells are detected. J Clin Oncol 2011, 29:1508-1511.
7.  Chambers AF, Groom AC, MacDonald IC: Dissemination and growth of 
cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-572.
8.  Bonnomet A, Brysse A, Tachsidis A, Waltham M, Thompson EW, Polette M, 
Gilles C: Epithelial-to-mesenchymal transitions and circulating tumor cells. 
J Mammary Gland Biol Neoplasia 2010, 15:261-273.
9. Chaff  er CL, Weinberg RA: A perspective on cancer cell metastasis. Science 
2011, 331:1559-1564.
10.  Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 
2011, 144:646-674.
11.  Goss PE, Chambers AF: Does tumour dormancy off  er a therapeutic target? 
Nat Rev Cancer 2010, 10:871-877.
12.  Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, Massagué 
J: Tumor self-seeding by circulating cancer cells. Cell 2009, 139:1315-1326.
13.  Comen E, Norton L, Massagué J: Clinical implications of cancer self-seeding. 
Nat Rev Clin Oncol 2011, 8:369-377.
14. Klein  CA:  Parallel progression of primary tumours and metastases. Nat Rev 
Cancer 2009, 9:302-312.
15.  Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, 
Doyle GV, Allard WJ, Terstappen LW, Hayes DF: Circulating tumor cells, 
disease progression, and survival in metastatic breast cancer. N Engl J Med 
2004, 351:781-791.
16.  Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, 
Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW: 
Circulating tumor cells: a novel prognostic factor for newly diagnosed 
metastatic breast cancer. J Clin Oncol 2005, 23:1420-1430.
17.  Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P, Marty M, 
Pierga JY: Single circulating tumor cell detection and overall survival in 
nonmetastatic breast cancer. Ann Oncol 2010, 21:729-733.
18.  Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, 
Andreopoulou E, Hall CS, Lodhi A, Jackson S, Lucci A: Detection of minimal 
residual disease in blood and bone marrow in early stage breast cancer. 
Cancer 2010, 116:3330-3337.
19.  Cristofanilli M, Braun S: Circulating tumor cells revisited. JAMA 2010, 
303:1092-1093.
20.  Rack BK, Schindlbeck C, Andergassen U, Schneeweiss A, Zwingers T, 
Lichtenegger W, Beckmann M, Sommer HL, Pantel K, Janni W; for the 
SUCCESS Study Group: Use of circulating tumor cells (CTC) in peripheral 
blood of breast cancer patients before and after adjuvant chemotherapy 
to predict risk for relapse: The SUCCESS trial [abstract]. J Clin Oncol 2010, 
28:15s.
21.  Müller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Jänicke F, Pantel K: 
Circulating tumor cells in breast cancer: correlation to bone marrow 
micrometastases, heterogeneous response to systemic therapy and low 
proliferative activity. Clin Cancer Res 2005, 11:3678-3685.
22.  Slade MJ, Payne R, Riethdorf S, Ward B, Zaidi SA, Stebbing J, Palmieri C, Sinnett 
HD, Kulinskaya E, Pitfi  eld T, McCormack RT, Pantel K, Coombes RC: 
Comparison of bone marrow, disseminated tumour cells and blood-
circulating tumour cells in breast cancer patients after primary treatment. 
Br J Cancer 2009, 100:160-166.
23.  Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, Rao SB, 
Eng-Wong J, Seillier-Moiseiwitsch F, Noone AM, Isaacs C: Circulating tumor 
cells: a useful predictor of treatment effi   cacy in metastatic breast cancer. 
J Clin Oncol 2009, 27:5153-5159.
24.  Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, 
Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S, Georgoulias V, 
Mavroudis D: Cytokeratin-19 mRNA-positive circulating tumor cells after 
adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 
2009, 27:2177-2184.
25.  Pierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S, de Cremoux P, 
Salmon R, Vincent-Salomon A, Marty M: Circulating tumor cell detection 
predicts early metastatic relapse after neoadjuvant chemotherapy in large 
operable and locally advanced breast cancer in a phase II randomized 
trial. Clin Cancer Res 2008, 14:7004-7010.
26.  Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, 
Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von 
Minckwitz G, Pantel K: Detection and HER2 expression of circulating tumor 
cells: prospective monitoring in breast cancer patients treated in the 
neoadjuvant GeparQuattro trial. Clin Cancer Res 2010, 16:2634-2645.
27.  Bidard FC, Mathiot C, Degeorges A, Etienne-Grimaldi MC, Delva R, Pivot X, 
Veyret C, Bergougnoux L, de Cremoux P, Milano G, Pierga JY: Clinical value of 
circulating endothelial cells and circulating tumor cells in metastatic 
breast cancer patients treated fi  rst line with bevacizumab and 
chemotherapy. Ann Oncol 2010, 21:1765-1771.
28.  SWOG S0500 [http://www.cancer.gov/clinicaltrials/search/view?cdrid=
504319&version=healthprofessional]
29.  GEPARQuattro trial [http://www.germanbreastgroup.de/studien/
neoadjuvant/geparquattro-/english-summary-.
html?lang=de_DE.UTF-8%2C+de_CH.U]
30.  SUCCESS [http://www.success-studie.de/]
31.  Liu Z, Fusi A, Schmittel A, Tinhofer I, Schneider A, Keilholz U: Eradication of 
EGFR-positive circulating tumor cells and objective tumor response with 
lapatinib and capecitabine. Cancer Biol Ther 2010, 10:860-864.
32.  Wiedswang G, Borgen E, Schirmer C, Kåresen R, Kvalheim G, Nesland JM, 
Naume B: Comparison of the clinical signifi  cance of occult tumor cells in 
blood and bone marrow in breast cancer. Int J Cancer 2006, 118:2013-2019.
33.  Banys M, Krawczyk N, Becker S, Jakubowska J, Staebler A, Wallwiener D, Fehm 
T, Rothmund R. The infl  uence of removal of primary tumor on incidence 
and phenotype of circulating tumor cells in primary breast cancer. Breast 
Cancer Res Treat 2011, in press.
34.  Daskalaki A, Agelaki S, Perraki M, Apostolaki S, Xenidis N, Stathopoulos E, 
Kontopodis E, Hatzidaki D, Mavroudis D, Georgoulias V: Detection of 
cytokeratin-19 mRNA-positive cells in the peripheral blood and bone 
marrow of patients with operable breast cancer. Br J Cancer 2009, 
101:589-597.
35.  Bartkowiak K, Wieczorek M, Buck F, Harder S, Moldenhauer J, Eff  enberger KE, 
Pantel K, Pater-Katalanic J, Brandt BH: Two-dimensional diff  erential gel 
electrophoresis of a cell line derived from a breast cancer micrometastasis 
revealed a stem/progenitor cell protein profi  le. J Proteome Res 2009, 
9:3158-3168.
36.  Benoy IH, Elst H, Philips M, Wuyts H, Van Dam P, Scharpé S, Van Marck E, 
Vermeulen PB, Dirix LY: Real-time RT-PCR detection of disseminated 
tumour cells in bone marrow has superior prognostic signifi  cance in 
comparison with circulating tumour cells in patients with breast cancer. Br 
J Cancer 2006, 94:672-680.
37.  Bidard FC, Vincent-Salomon A, Sigal-Zafrani B, Diéras V, Mathiot C, Mignot L, 
Thiery JP, Sastre-Garau X, Pierga JY: Prognosis of women with stage IV 
breast cancer depends on detection of circulating tumor cells rather than 
disseminated tumor cells. Ann Oncol 2008, 19:496-500.
38.  Pierga JY, Bonneton C, Vincent-Salomon A, de Cremoux P, Nos C, Blin N, 
Pouillart P, Thiery JP, Magdelénat H: Clinical signifi  cance of 
immunocytochemical detection of tumor cells using digital microscopy in 
peripheral blood and bone marrow of breast cancer patients. Clin Cancer 
Res 2004, 10:1392-1400.
39.  Peeters DJ, Van den Eynden GG, van Dam PJ, Prové A, Benoy IH, van Dam PA, 
Vermeulen PB, Pauwels P, Peeters M, Van Laere SJ, Dirix LY: Circulating 
tumour cells in the central and the peripheral venous compartment in 
patients with metastatic breast cancer. Br J Cancer 2011, 104:1472-1477.
40.  Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch 
M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen 
LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW: Circulating tumor cells in 
patients with breast cancer dormancy. Clin Cancer Res 2004, 10:8152-8162.
41.  Alix-Panabières C, Vendrell JP, Slijper M, Pellé O, Barbotte E, Mercier G, Jacot W, 
Fabbro M, Pantel K: Full-length cytokeratin-19 is released by human tumor 
Bednarz-Knoll et al. Breast Cancer Research 2011, 13:228
http://breast-cancer-research.com/content/13/6/228
Page 9 of 11cells: a potential role in metastatic progression of breast cancer. Breast 
Cancer Res 2009, 11:R39.
42.  Rossi E, Basso U, Celadin R, Zilio F, Pucciarelli S, Aieta M, Barile C, Sava T, 
Bonciarelli G, Tumolo S, Ghiotto C, Magro C, Jirillo A, Indraccolo S, Amadori A, 
Zamarchi R: M30 neoepitope expression in epithelial cancer: quantifi  cation 
of apoptosis in circulating tumor cells by CellSearch analysis. Clin Cancer 
Res 2010, 16:5233-5243.
43.  Flores LM, Kindelberger DW, Ligon AH, Capelletti M, Fiorentino M, Loda M, 
Cibas ES, Jänne PA, Krop IE: Improving the yield of circulating tumour cells 
facilitates molecular characterisation and recognition of discordant HER2 
amplifi  cation in breast cancer. Br J Cancer 2010, 102:1495-1502.
44.  Königsberg R, Obermayr E, Bises G, Pfeiler G, Gneist M, Wrba F, De Santis M, 
Zeillinger R, Hudec M, Dittrich C: Detection of EpCAM positive and negative 
circulating tumor cells in metastatic breast cancer patients. Acta Oncol 
2011, 50:700-710.
45.  Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, Martens 
JW, Gratama JW, Sleijfer S, Foekens JA: Anti-epithelial cell adhesion 
molecule antibodies and the detection of circulating normal-like breast 
tumor cells. J Natl Cancer Inst 2009, 101:61-66.
46.  Mostert B, Kraan J, Bolt-de Vries J, van der Spoel P, Sieuwerts AM, Schutte M, 
Timmermans AM, Foekens R, Martens JW, Gratama JW, Foekens JA, Sleijfer S: 
Detection of circulating tumor cells in breast cancer may improve through 
enrichment with anti-CD146. Breast Cancer Res Treat 2011, 127:33-41.
47. Eff  enberger KE, Borgen E, Eulenburg CZ, Bartkowiak K, Grosser A, Synnestvedt 
M, Kaaresen R, Brandt B, Nesland JM, Pantel K, Naume B: Detection and 
clinical relevance of early disseminated breast cancer cells depend on 
their cytokeratin expression pattern. Breast Cancer Res Treat 2011, 
125:729-738.
48.  Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, Kieu C, Papior P, 
Baeuerle PA, Munz M, Gires O: Nuclear signalling by tumour-associated 
antigen EpCAM. Nat Cell Biol 2009, 11:162-171.
49.  Polyak K, Weinberg RA: Transitions between epithelial and mesenchymal 
states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009, 
9:265-273.
50.  Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S: Stem cell and 
epithelial-mesenchymal transition markers are frequently overexpressed 
in circulating tumor cells of metastatic breast cancer patients. Breast 
Cancer Res 2009, 11:R46.
51.  Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN, Gao H, Jackson SA, 
Giordano A, Hortobagyi GN, Cristofanilli M, Lucci A, Reuben JM: Expression of 
epithelial-mesenchymal transition-inducing transcription factors in 
primary breast cancer: The eff  ect of neoadjuvant therapy. Int J Cancer 2011, 
in press.
52.  Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, Palazzo 
A, Saltarelli R, Spremberg F, Cortesi E, Gazzaniga P: Epithelial-mesenchymal 
transition and stemness features in circulating tumor cells from breast 
cancer patients. Breast Cancer Res Treat 2011, in press.
53.  Gradilone A, Raimondi C, Nicolazzo C, Petracca A, Gandini O, Vincenzi B, Naso 
G, Aglianò AM, Cortesi E, Gazzaniga P: Circulating tumor cells lacking 
cytokeratin in breast cancer: the importance of being mesenchymal. J Cell 
Mol Med 2011, 15:1066-1070.
54.  Bednarz N, Eltze E, Semjonow A, Rink M, Andreas A, Mulder L, Hannemann J, 
Fisch M, Pantel K, Weier U-HG, Bielawski KP, Brandt B: BRCA1 loss pre-existing 
in small subpopulations of prostate cancer is associated with advanced 
disease and metastatic spread to lymph nodes and peripheral blood. Clin 
Cancer Res 2010, 16:3340-3348.
55.  Mor-Vaknin   N, Punturieri A, Sitwala K, Markovitz DM: Vimentin is secreted by 
activated macrophages. Nat Cell Biol 2003, 5:59-63.
56.  May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA: Epithelial-
mesenchymal transition and cancer stem cells: a dangerously dynamic 
duo in breast cancer progression. Breast Cancer Res 2011, 13:202.
57.  Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard 
F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg 
RA: The epithelial-mesenchymal transition generates cells with properties 
of stem cells. Cell 2008, 133:704-715.
58.  Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis 
D, Georgoulias V: Circulating tumor cells with a putative stem cell 
phenotype in peripheral blood of patients with breast cancer. Cancer Lett 
2010, 288:99-106.
59.  Gradilone A, Naso G, Raimondi C, Cortesi E, Gandini O, Vincenti B, Saltarelli R, 
Chiapparono E, Spremberg F, Cristofanilli M, Frati L, Agliano AM, Gazzaniga P: 
Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): 
prognosis, drug resistance and phenotypic characterization. Ann Oncol 
2011, 22:86-92.
60.  Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C, Cappadona S, 
Biganzoli L, Giannini A, Di Leo A: Correlation of HER2 status between 
primary tumors and corresponding circulating tumor cells in advanced 
breast cancer patients. Breast Cancer Res Treat 2009, 118:523-530.
61.  Munzone E, Nolé F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, Curigliano G, 
Minchella I, Adamoli L, Cassatella MC, Casadio C, Sandri MT: Changes of HER2 
status in circulating tumor cells compared with the primary tumor during 
treatment for advanced breast cancer. Clin Breast Cancer 2010, 10:392-397.
62.  Wülfi  ng P, Borchard J, Buerger H, Heidl S, Zänker KS, Kiesel L, Brandt B: HER2-
positive circulating tumor cells indicate poor clinical outcome in stage I to 
III breast cancer patients. Clin Cancer Res 2006, 12:1715-1720.
63.  Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, 
Löhberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker 
K, Kasimir-Bauer S, Wallwiener D, Pantel K: HER2 status of circulating tumor 
cells in patients with metastatic breast cancer: a prospective, multicenter 
trial. Breast Cancer Res Treat 2010, 124:403-412.
64.  Kallergi G, Agelaki S, Kalykaki A, Stournaras C, Mavroudis D, Georgoulias V: 
Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in 
circulating tumor cells of breast cancer patients. Breast Cancer Res 2008, 
10:R80.
65.  Aktas B, Müller V, Tewes M, Zeitz J, Kasimir-Bauer S, Loehberg CR, Rack B, 
Schneeweiss A, Fehm T: Comparison of estrogen and progesterone 
receptor status of circulating tumor cells and the primary tumor in 
metastatic breast cancer patients. Gynecol Oncol 2011, 122:356-360.
66.  Alix-Panabières C, Riethdorf S, Pantel K: Circulating tumor cells and bone 
marrow micrometastasis. Clin Cancer Res 2008, 14:5013-5021.
67.  Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, 
Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber 
DA, Toner M: Isolation of rare circulating tumour cells in cancer patients by 
microchip technology. Nature 2007, 450:1235-1239.
68.  Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra 
E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, 
Settleman J, Tompkins RG, Lynch TJ, Toner M, Haber DA: Detection of 
mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008 
359:366-377.
69.  Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg 
SM, Shah AM, Smas ME, Korir GK, Floyd FP Jr, Gilman AJ, Lord JB, Winokur D, 
Springer S, Irimia D, Nagrath S, Sequist LV, Lee RJ, Isselbacher KJ, Maheswaran 
S, Haber DA, Toner M: Isolation of circulating tumor cells using a 
microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 2010, 
107:18392-18397.
70.  Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, 
Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, 
Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber DA, 
Maheswaran S: Isolation and characterization of circulating tumor cells 
from patients with localized and metastatic prostate cancer. Sci Transl Med 
2010, 2:25ra23.
71.  Saliba AE, Saias L, Psychari E, Minc N, Simon D, Bidard FC, Mathiot C, Pierga JY, 
Fraisier V, Salamero J, Saada V, Farace F, Vielh P, Malaquin L, Viovy JL: 
Microfl  uidic sorting and multimodal typing of cancer cells in self-
assembled magnetic arrays. Proc Natl Acad Sci U S A 2010, 107:14524-14529.
72.  Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh KH, Yu W, Xiao W, Davis MM, 
Pease RF, Mindrinos MN, Jeff  rey SS, Davis RW: Isolating highly enriched 
populations of circulating epithelial cells and other rare cells from blood 
using a magnetic sweeper device. Proc Natl Acad Sci U S A 2009, 
106:3970-3975.
73.  Rolle A, Günzel R, Pachmann U, Willen B, Höff  ken K, Pachmann K: Increase in 
number of circulating disseminated epithelial cells after surgery for non-
small cell lung cancer monitored by MAINTRAC(R) is a predictor for 
relapse: A preliminary report. World J Surg Oncol 2005, 3:18.
74.  Ntouroupi TG, Ashraf SQ, McGregor SB, Turney BW, Seppo A, Kim Y, Wang X, 
Kilpatrick MW, Tsipouras P, Tafas T, Bodmer WF: Detection of circulating 
tumour cells in peripheral blood with an automated scanning 
fl  uorescence microscope. Br J Cancer 2008, 99:789-795.
75.  Deng G, Herrler M, Burgess D, Manna E, Krag D, Burke JF: Enrichment with 
anti-cytokeratin alone or combined with anti-EpCAM antibodies 
signifi  cantly increases the sensitivity for circulating tumor cell detection in 
metastatic breast cancer patients. Breast Cancer Res 2008, 10:R69.
Bednarz-Knoll et al. Breast Cancer Research 2011, 13:228
http://breast-cancer-research.com/content/13/6/228
Page 10 of 1176.  Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, 
Valero V, Fritsche HA, Cristofanilli M: Comparison of assay methods for 
detection of circulating tumor cells (CTCs) in metastatic breast cancer 
(MBC): AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex 
CellSearch™ system. Int J Cancer 2011, in press.
77.  Alix-Panabières C, Vendrell JP, Pellé O, Rebillard X, Riethdorf S, Müller V, Fabbro 
M, Pantel K: Detection and characterization of putative metastatic 
precursor cells in cancer patients. Clin Chem 2007, 53:537-539.
78.  Lu J, Fan T, Zhao Q, Zeng W, Zaslavsky E, Chen JJ, Frohman MA, Golightly MG, 
Madajewicz S, Chen WT: Isolation of circulating epithelial and tumor 
progenitor cells with an invasive phenotype from breast cancer patients. 
Int J Cancer 2010, 126:669-683.
79.  Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schütze K, Capron F, Franco D, 
Pazzagli M, Vekemans M, Lacour B, Bréchot C, Paterlini-Bréchot P: Isolation by 
size of epithelial tumor cells : a new method for the 
immunomorphological and molecular characterization of 
circulatingtumor cells. Am J Pathol 2000, 156:57-63.
80.  Pinzani P, Salvadori B, Simi L, Bianchi S, Distante V, Cataliotti L, Pazzagli M, 
Orlando C: Isolation by size of epithelial tumor cells in peripheral blood of 
patients with breast cancer: correlation with real-time reverse 
transcriptase-polymerase chain reaction results and feasibility of 
molecular analysis by laser microdissection. Hum Pathol 2006, 37:711-718.
81.  Hofman VJ, Ilie MI, Bonnetaud C, Selva E, Long E, Molina T, Vignaud JM, Fléjou 
JF, Lantuejoul S, Piaton E, Butori C, Mourad N, Poudenx M, Bahadoran P, Sibon 
S, Guevara N, Santini J, Vénissac N, Mouroux J, Vielh P, Hofman PM: 
Cytopathologic detection of circulating tumor cells using the isolation by 
size of epithelial tumor cell method: promises and pitfalls. Am J Clin Pathol 
2011, 135:146-156.
82.  Krivacic RT, Ladanyi A, Curry DN, Hsieh HB, Kuhn P, Bergsrud DE, Kepros JF, 
Barbera T, Ho MY, Chen LB, Lerner RA, Bruce RH: A rare-cell detector for 
cancer. Proc Natl Acad Sci U S A 2004, 101:10501-10504.
83.  Somlo G, Lau SK, Frankel P, Hsieh HB, Liu X, Yang L, Krivacic R, Bruce RH: 
Multiple biomarker expression on circulating tumor cells in comparison to 
tumor tissues from primary and metastatic sites in patients with locally 
advanced/infl  ammatory, and stage IV breast cancer, using a novel 
detection technology. Breast Cancer Res Treat 2011, in press.
84.  Gascoyne PR, Noshari J, Anderson TJ, Becker FF: Isolation of rare cells from 
cell mixtures by dielectrophoresis. Electrophoresis 2009, 30:1388-1398.
85.  Tan SJ, Lakshmi RL, Chen P, Lim WT, Yobas L, Lim CT: Versatile label free 
biochip for the detection of circulating tumor cells from peripheral blood 
in cancer patients. Biosens Bioelectron 2010, 26:1701-1705.
86.  Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, 
Chlouverakis G, Stathopoulos E, Lianidou E, Georgoulias V, Mavroudis D: 
Prognostic value of the molecular detection of circulating tumor cells 
using a multimarker reverse transcription-PCR assay for cytokeratin 19, 
mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res 2008, 
14:2593-2600.
87.  Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, 
Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, 
Georgoulias V, Mavroudis D: Diff  erent prognostic value of cytokeratin-19 
mRNA positive circulating tumor cells according to estrogen receptor and 
HER2 status in early-stage breast cancer. J Clin Oncol 2007, 25:5194-5202.
88.  Kallergi G, Markomanolaki H, Giannoukaraki V, Papadaki MA, Strati A, Lianidou 
ES, Georgoulias V, Mavroudis D, Agelaki S: Hypoxia-inducible factor-1alpha 
and vascular endothelial growth factor expression in circulating tumor 
cells of breast cancer patients. Breast Cancer Res 2009, 11:R84.
89.  Markou A, Strati A, Malamos N, Georgoulias V, Lianidou ES: Molecular 
characterization of circulating tumor cells in breast cancer by a liquid 
bead array hybridization assay. Clin Chem 2011, 57:421-430.
90.  Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, Haley B, Frenkel E, Euhus 
D, Leitch M, Osborne C, Cliff  ord E, Perkins S, Beitsch P, Khan A, Morrison L, 
Herlyn D, Terstappen LW, Lane N, Wang J, Uhr J: uPAR and HER-2 gene status 
in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci 
U S A 2006, 103:17361-17365.
91. Fehm  T,  Hoff  mann O, Aktas B, Becker S, Solomayer EF, Wallwiener D, Kimmig 
R, Kasimir-Bauer S: Detection and characterization of circulating tumor 
cells in blood of primary breast cancer patients by RT-PCR and 
comparison to status of bone marrow disseminated cells. Breast Cancer Res 
2009,11:R59.
doi:10.1186/bcr2940
Cite this article as: Bednarz-Knoll N, et al.: Clinical relevance and biology of 
circulating tumor cells. Breast Cancer Research 2011, 13:228.
Bednarz-Knoll et al. Breast Cancer Research 2011, 13:228
http://breast-cancer-research.com/content/13/6/228
Page 11 of 11